JB Pharma continues winning streak with focus on chronic therapies

In terms of product and business, almost 48 per cent contribution was coming from chronic therapy, and the endeavour is to reach 60 per cent. As a company, we were traditionally very weak at launching new products, and our new product contribution was less than one per cent. However, we endured the challenge and started developing the life cycle of new brands, said Dilip Singh Rathore

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/ty1DhbX
via